Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
Open Access
- 12 August 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 5 (11) , 1236-1244
Abstract
Patients with heart failure (HF) face a challenging prognosis, with a 50% mortality rate in 5 years. In addition, HF remains a leading cause of hospitalization for adults and costs the US health care system approximately $40 billion per year.1 Over the past 3 decades, therapies that inhibit or alter neurohormonal pathways have led to improvements in morbidity and mortality among patients with HF with reduced ejection fraction (HFrEF).Keywords
This publication has 24 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance MeasuresCirculation, 2014
- Epidemiology of Heart FailureCirculation Research, 2013
- Forecasting the Impact of Heart Failure in the United StatesCirculation: Heart Failure, 2013
- Cost Estimation of Cardiovascular Disease Events in the USPharmacoEconomics, 2011
- Lifetime Costs of Medical Care After Heart Failure DiagnosisCirculation: Cardiovascular Quality and Outcomes, 2011
- Ten arguments for a societal perspective in the economic evaluation of medical innovationsThe European Journal of Health Economics, 2009
- Heart failure disease management programs: A cost-effectiveness analysisAmerican Heart Journal, 2008
- Cardiovascular Disease in the Developing World and Its Cost-Effective ManagementCirculation, 2005